Tackling the Innovation Crisis in Drug Discovery and Development

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays.

Together with Molecule’s distributed IP ownership platform, which enables stakeholders in drug development to collaborate and share ownership of the IP they are working to develop, Arctoris and Molecule intend to take strides towards making drug discovery and development faster, cheaper, less risk-prone, and more viable at all levels.

“Drug discovery researchers worldwide face enormous challenges posed by a widespread lack of reproducibility and the limited availability of standardized, structured, high-quality data. By partnering with Molecule, we intend to make drug discovery and development more democratic, collaborative, and efficient in the interest of bringing higher-quality therapeutics to patients faster through the combination of robotics, AI and a distributed research platform,” said Martin-Immanuel Bittner, MD DPhil, Co-Founder, and CEO of Arctoris.


Stem Cell Manufacturing in Stem Cell Therapy, Drug Discovery & Development, Stem Cell Banking, and More (2020-2025)

The Stem Cell Manufacturing market is projected to grow with a CAGR of nearly 3.3% over the forecast period.

The major factors attributing to the growth of the market include the technological advancements in stem cell manufacturing and preservation and growing public awareness about the therapeutic potency of stem cell products.

According to California Institute for Regenerative Medicine, for the millions of people around the world who suffer from incurable diseases and injury, Stem Cell Awareness Day, October 11th is a day to celebrate the scientific advances made to-date. Research and academic institutions and educators are encouraged to participate by hosting public talks and other activities and events in their community. Furthermore, the growing growing public-private investments and funding in stem cell-based research is boosting the market growth. However, the gaining popularity of alternative procedures is the major drawback of market growth.


Global Computational Medicine and Drug Discovery Software Market 2020 Competitive Scenario – Entelos, Rhenovia Pharma Limited, Biognos Ab

Global Computational Medicine and Drug Discovery Software Market 2020 by Company, Regions, Type, and Application, Forecast to 2025 provides extensive and highly detailed information on the market, by showing the deep research and giving comprehensive insights into this sector. The report presents a description of all the essential focuses concerning the global Computational Medicine and Drug Discovery Software market.

It successfully displays the complete scenario of the global and an individual analysis of the various regional segments. The report analyzes historical data, facts, current growth factors, and market segments including competitor segment, product type segment, end use/application segment, and geography segment.


Drug discovery & development award winners revealed at SLAS2020

The winners of the 2020 Scientists’ Choice Awards® were announced by SelectScience Editor-in-Chief Kerry Parker to an audience of industry leaders and scientists in San Diego.
Now in their 13th year, the annual Scientists’ Choice Awards recognize the new technologies which have had the greatest impact on global scientific advancement. More scientists than ever have got involved in the drug discovery and development category this year by nominating and voting for their favorite lab products online.
10 runners-up were:

– xCELLigence RTCA eSight™ multimode real-time cell analyzer, from ACEA Biosciences – A part of Agilent
– CLARIOstar® Plus multi-mode microplate reader, from BMG LABTECH
– Corning® Elplasia® plates for 3D cell culture, from Corning Life Sciences
– OrganoPlate® Graft plates for vascularization of 3D tissues, from MIMETAS B.V.
– FLIPR Penta®  high-throughput cellular screening system, from Molecular Devices®
– Dianthus molecular interaction screening system, from NanoTemper Technologies
– Intellicyt iQue3 flow cytometry platform, from Sartorius Group
– Spar® Cyto multi-mode plate reader with fluorescence imaging and cytometry capabilities, from Tecan
– Thermo Scientific™ Orbitrap Exploris ™ 480 mass spectrometers, from Thermo Fisher Scientific
– chameleon automated sample preparation system for cryo-EM, from SPT Labtec

Novel and selective inactivators of Triosephosphate isomerase with anti-trematode activity
Trematode infections such as schistosomiasis and fascioliasis cause significant morbidity in an estimated 250 million people worldwide and the associated agricultural losses are estimated at more than US$ 6 billion per year. Current chemotherapy is limited. Triosephosphate isomerase (TIM), an enzyme of the glycolytic pathway, has emerged as a useful drug target in many parasites, including Fasciola hepatica TIM (FhTIM). We identified 21 novel compounds that selectively inhibit this enzyme.

Using microscale thermophoresis we explored the interaction between target and compounds and identified a potent interaction between the sulfonyl-1,2,4-thiadiazole (compound 187) and FhTIM, which showed an IC50 of 5 µM and a Kd of 66 nM. In only 4 hours, this compound killed the juvenile form of F. hepatica with an IC50 of 3 µM, better than the reference drug triclabendazole (TCZ). Interestingly, we discovered in vitro inhibition of FhTIM by TCZ, with an IC50 of 7 µM suggesting a previously uncharacterized role of FhTIM in the mechanism of action of this drug. Compound 187 was also active against various developmental stages of Schistosoma mansoni.

The low toxicity in vitro in different cell types and lack of acute toxicity in mice was demonstrated for this compound, as was demonstrated the efficacy of 187 in vivo in F. hepatica infected mice. Finally, we obtained the first crystal structure of FhTIM at 1.9 Å resolution which allows us to use docking to suggest a mechanism of interaction between compound 187 and TIM. In conclusion, we describe a promising drug candidate to control neglected trematode infections in human and animal health